MRC Technology has entered into an agreement with Genentech, a wholly owned member of the Roche Group, for an exclusive license to a series of small molecule drug candidates for the potential treatment of neurological disease. Under the agreement, MRC will receive an upfront payment and is eligible to receive clinical development milestones and royalties on sales. Financial terms and the target of the small molecule project were not disclosed. MRC Technology’s CTD initiated a small m...